Diplomat Pharmacy Inc

Diplomat Pharmacy — Q2 2019 Earnings Presentation

15 slides from Diplomat Pharmacy's earnings presentation, Aug 9, 2019

  1. Slide 1: Non-GAAP Information and Forward-Looking Statements

    NON-GAAP INFORMATION We define Adjusted EBITDA as net income (loss) before interest expense, income taxes, depreciation and amortization, share-based compensation, change in fair value of contingent consideration and other merger and acquisition-related expenses, restructuring and impairment charges

  2. Slide 2: Opening Remarks

    Opening Remarks Brian Griffin, Chairman and CEO Copyright © 2019 by Diplomat Pharmacy Inc. Diplomat is a registered trademark of Diplomat Pharmacy Inc. All rights reserved.

  3. Slide 3: 2Q 2019 Highlights

    $1.3B (-9%) Revenue $19M (-55%) Adjusted EBITDA1 • • • • • • Strong growth in infusion Impact of generics Payer reimbursement compression Volume deterioration in certain therapy classes Previously announced PBM contract losses & pricing concessions Reimbursement compression Lower earned rebates and

  4. Slide 4: Putting Patients First

    JACQUE DIPLOMAT PATIENT Infrastructure Employees Specialty Pharmacy Solutions Manufacturer Services Infusion Innovation 5 PBM Putting Patients First

  5. Slide 5: Financial Results

    Financial Results Dan Davison, CFO Copyright © 2019 by Diplomat Pharmacy Inc. Diplomat is a registered trademark of Diplomat Pharmacy Inc. All rights reserved.

  6. Slide 6: 2Q 2019 Financial Results Summary

    2Q18 2Q19 Revenue: $1.4B Revenue: $1.3B Adjusted EBITDA1: $43M Adjusted EBITDA1: $19M GAAP Net Loss: ($4.0M) GAAP Net Loss2: ($159M) GAAP EPS2: ($2.13) GAAP EPS: ($0.05) 1. A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net income (loss), as prepared in accordance with GAAP can be found

  7. Slide 7: 2Q 2019 Segment Details

    Specialty PBM Revenue: $1.2B Net Sales/Rx: $5,162 Revenue: $90M Rx volume*: 942,000 Gross margin: 5.2% Gross profit/Rx: $264 Gross margin: 10.7% Gross profit/Rx: $10 Rx volume: 235,000 * Adjusted to 30-day equivalent, where a 90-day prescription is counted as three 30-day prescriptions filled. 8 2Q

  8. Slide 8: Snapshot of Credit Facility Covenant Metrics

    Maximum Total Net Leverage Ratio2 Amended terms became effective August 6, 2019, supporting financial flexibility. Minimum Interest Coverage Ratio3 Diplomat agreed to permanently reduce its revolving line of credit from $250M to $200M. 1. Please refer to our Current Report on Form 8-K filed with the

  9. Slide 9: Revised 2019 Full-Year Outlook

    Total Revenue Total Adjusted EBITDA1 $87M–$93M $4.7B–$5.0B Specialty Revenue PBM Revenue GAAP Net Income GAAP EPS ($201M)–($191M) $4.4B–$4.6B $325M–$375M ($2.69)–($2.55) 1. A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net income (loss), as prepared in accordance with GAAP can be found

  10. Slide 10: 2019 Key Headwinds and Tailwinds

    Headwinds Payer reimbursement pressure Tailwinds New core specialty and infusion contract awards Narrowing of specialty pharmacy networks Data & analytics monetization Specialty pharmacy member channel management Uptake of new and existing generics and biosimilars New indications for existing produc

  11. Slide 11: Appendix: Supplemental Financial Information

    Appendix Supplemental Financial Information Copyright © 2019 by Diplomat Pharmacy Inc. Diplomat is a registered trademark of Diplomat Pharmacy Inc. All rights reserved.

  12. Slide 12: Reconciliation of Net Loss to Adjusted EBITDA

    For the three months ended June 30, For the six months ended June 30, 2019 2018 2019 2018 (dollars in thousands) (unaudited) Net loss Depreciation Amortization Interest expense Income tax expense EBITDA $ (159,462) 1,641 18,423 10,170 434 $ (3,964) 1,590 22,629 10,392 1,740 $ (173,763) 3,325 38,133

  13. Slide 13: Revised 2019 Full-Year Outlook: GAAP to Non-GAAP Reconciliation

    Reconciliation of GAAP to Adjusted EBITDA (dollars in thousands) (unaudited) Range Low High Net loss attributable to Diplomat Pharmacy, Inc. Depreciation and amortization Interest expense 1 Income tax expense EBITDA $ (201,167) 75,500 42,000 2,000 $ (190,617) 74,500 41,000 1,500 $ (81,667) $ (73,617

  14. Slide 14: Supplemental Information: Net Debt

    As of June 30, 2019 As of December 31, 2018 (dollars in thousands) (unaudited) Borrowings on line of credit Term Loan A Term Loan B Contingent consideration Cash Net Debt1 125,000 138,750 320,000 6,838 (5,771) 176,300 142,500 322,000 6,895 (9,485) 584,817 638,210 1 Net debt is defined as total debt

  15. Slide 15: Supplemental Information: Net Debt

    DIPLOMATA, Supplemental Information: Net Debt! As of June 30,2019 As of December 31, 2018 lars in th in naudit Borrowings on line of credit 125,000 176,300 Term Loan A 138,750 142,500 Term Loan B 320,000 322,000 Contingent consideration 6,838 6,895 Cash (5,771) (9,485) Net Debt! 584,817 638,210 ' Ne

Diplomat Pharmacy — Q2 2019 Earnings Presentation on 6ix